Synopsis
Synopsis
0
VMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Apo-propafenone
2. Arythmol
3. Baxarytmon
4. Cuxafenon
5. Fenoprain
6. Hydrochloride, Propafenone
7. Jutanorm
8. Nistaken
9. Norfenon
10. Pintoform
11. Prolecofen
12. Propafenon Al
13. Propafenon Hexal
14. Propafenon Minden
15. Propafenone
16. Propafenone Hydrochloride, (r)-isomer
17. Propafenone Hydrochloride, (s)-isomer
18. Propafenone, (+-)-isomer
19. Propafenone, (r)-isomer
20. Propafenone, (s)-isomer
21. Propamerck
22. Rythmol
23. Rytmo-puren
24. Rytmogenat
25. Rytmonorm
26. Sa 79
27. Sa-79
28. Sa79
1. 34183-22-7
2. Propafenone Hcl
3. Rythmol
4. Rytmonorm
5. Arythmol
6. Pronon
7. Rythmol Sr
8. Propafenone (hydrochloride)
9. Propafenon Hydrochlorid
10. 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenylpropan-1-one Hydrochloride
11. Sa-79 (hydrochloride)
12. 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one Hydrochloride
13. 1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one Hydrochloride
14. 33xch0hocd
15. Nsc-758640
16. 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one;hydrochloride
17. Mls000069682
18. Chebi:8466
19. Baxarytmon
20. Fenoprain
21. 2'-(2-hydroxy-3-(propylamino)propoxy)-3-phenylpropiophenone Hydrochloride
22. 1-propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-, Hydrochloride
23. Rhythmonorm
24. Smr000058493
25. 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-1-propanone Hydrochloride
26. Sa 79
27. Propafenon Hydrochlorid [german]
28. Sr-01000000192
29. Einecs 251-867-9
30. Unii-33xch0hocd
31. Wz 884
32. Propafenone, Hcl
33. Prestwick_831
34. Rythmol (tn)
35. Mfcd00079243
36. Propafenone Hydrochloride [usan:usp:jan]
37. Opera_id_1835
38. Schembl41412
39. Mls001148185
40. Mls002222267
41. Spectrum1503935
42. Chembl1201063
43. Hy-b0432a
44. Dtxsid101017233
45. Hms1569d19
46. Hms1922m16
47. Pharmakon1600-01503935
48. Bcp28548
49. Tox21_500919
50. Ccg-39061
51. Nsc758640
52. Propafenone Hydrochloride [mi]
53. Akos008901409
54. Propafenone Hydrochloride (jp17/usp)
55. Ks-5030
56. Lp00919
57. Nsc 758640
58. Propafenone Hydrochloride [jan]
59. Propafenone Hydrochloride [usan]
60. Propiophenone, 2'-(2-hydroxy-3-(propylamino)propoxy)-3-phenyl-, Hydrochloride
61. Ncgc00094230-01
62. Ncgc00094230-02
63. Ncgc00094230-03
64. Ncgc00094230-04
65. Ncgc00094230-05
66. Ncgc00261604-01
67. Propafenone Hydrochloride [mart.]
68. Propafenone Hydrochloride [vandf]
69. Ac-11360
70. Ac-33196
71. Propafenone Hydrochloride [usp-rs]
72. Propafenone Hydrochloride [who-dd]
73. Db-048579
74. Eu-0100919
75. Ft-0630579
76. P2301
77. En300-51034
78. D00640
79. P 4670
80. Propafenone Hydrochloride [ep Monograph]
81. Propafenone Hydrochloride [orange Book]
82. Propafenone Hydrochloride [usp Monograph]
83. 183p227
84. A822113
85. J-019481
86. Sr-01000000192-2
87. Sr-01000000192-6
88. Q27108087
89. Z802671518
90. 1-(2-[2-hydroxy-3-(propylamino)propoxy]phenyl)-3-phenyl-1propanone
91. 2'-(2-hydroxy-3-propylaminopropoxy)-3-phenylpropiophenone Hydrochloride
92. Propafenone Hydrochloride, European Pharmacopoeia (ep) Reference Standard
93. 1-[2-[2-oxidanyl-3-(propylamino)propoxy]phenyl]-3-phenyl-propan-1-one Hydrochloride
94. 2-hydroxy-3-[2-(3-phenylpropanoyl)phenoxy]-n-propylpropan-1-aminium Chloride
95. Hydron;1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylpropan-1-one;chloride
96. Propafenone Hydrochloride, United States Pharmacopeia (usp) Reference Standard
Molecular Weight | 377.9 g/mol |
---|---|
Molecular Formula | C21H28ClNO3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 11 |
Exact Mass | 377.1757714 g/mol |
Monoisotopic Mass | 377.1757714 g/mol |
Topological Polar Surface Area | 58.6 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 368 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Propafenone hydrochloride |
Drug Label | Propafenone hydrochloride is an antiarrhythmic drug supplied in scored, film-coated tablets of 150 and 225 mg for oral administration. Propafenone has some structural similarities to beta-blocking agents.Chemically, propafenone hydrochloride (HCl) is... |
Active Ingredient | Propafenone hydrochloride |
Dosage Form | Tablet; Capsule, extended release |
Route | Oral |
Strength | 150mg; 300mg; 225mg; 425mg; 325mg |
Market Status | Prescription |
Company | Vintage Pharms; Ani Pharms; Par Pharm; Watson Labs; Mutual Pharm |
2 of 6 | |
---|---|
Drug Name | Rythmol |
PubMed Health | Propafenone (By mouth) |
Drug Classes | Antiarrhythmic, Group IC |
Drug Label | RYTHMOL SR (propafenone hydrochloride) is an antiarrhythmic drug supplied in extended-release capsules of 225, 325 and 425mg for oral administration.Chemically, propafenone hydrochloride is 2-[2-Hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophe... |
Active Ingredient | Propafenone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 150mg; 300mg; 225mg |
Market Status | Prescription |
Company | Glaxosmithkline |
3 of 6 | |
---|---|
Drug Name | Rythmol sr |
PubMed Health | Propafenone (By mouth) |
Drug Classes | Antiarrhythmic, Group IC |
Drug Label | RYTHMOL SR (propafenone hydrochloride) is an antiarrhythmic drug supplied in extended-release capsules of 225, 325 and 425mg for oral administration.Chemically, propafenone hydrochloride is 2-[2-Hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophe... |
Active Ingredient | Propafenone hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 225mg; 425mg; 325mg |
Market Status | Prescription |
Company | Glaxosmithkline |
4 of 6 | |
---|---|
Drug Name | Propafenone hydrochloride |
Drug Label | Propafenone hydrochloride is an antiarrhythmic drug supplied in scored, film-coated tablets of 150 and 225 mg for oral administration. Propafenone has some structural similarities to beta-blocking agents.Chemically, propafenone hydrochloride (HCl) is... |
Active Ingredient | Propafenone hydrochloride |
Dosage Form | Tablet; Capsule, extended release |
Route | Oral |
Strength | 150mg; 300mg; 225mg; 425mg; 325mg |
Market Status | Prescription |
Company | Vintage Pharms; Ani Pharms; Par Pharm; Watson Labs; Mutual Pharm |
5 of 6 | |
---|---|
Drug Name | Rythmol |
PubMed Health | Propafenone (By mouth) |
Drug Classes | Antiarrhythmic, Group IC |
Drug Label | RYTHMOL SR (propafenone hydrochloride) is an antiarrhythmic drug supplied in extended-release capsules of 225, 325 and 425mg for oral administration.Chemically, propafenone hydrochloride is 2-[2-Hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophe... |
Active Ingredient | Propafenone hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 150mg; 300mg; 225mg |
Market Status | Prescription |
Company | Glaxosmithkline |
6 of 6 | |
---|---|
Drug Name | Rythmol sr |
PubMed Health | Propafenone (By mouth) |
Drug Classes | Antiarrhythmic, Group IC |
Drug Label | RYTHMOL SR (propafenone hydrochloride) is an antiarrhythmic drug supplied in extended-release capsules of 225, 325 and 425mg for oral administration.Chemically, propafenone hydrochloride is 2-[2-Hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophe... |
Active Ingredient | Propafenone hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 225mg; 425mg; 325mg |
Market Status | Prescription |
Company | Glaxosmithkline |
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-03-07
Pay. Date : 2013-02-15
DMF Number : 10641
Submission : 1993-12-16
Status : Active
Type : II
Certificate Number : R1-CEP 2005-236 - Rev 03
Issue Date : 2018-06-08
Type : Chemical
Substance Number : 2103
Status : Valid
Date of Issue : 2022-06-24
Valid Till : 2025-07-02
Written Confirmation Number : WC-0102
Address of the Firm :
NDC Package Code : 12598-6216
Start Marketing Date : 1992-12-16
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1h/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING
Registrant Name : Abbott Korea Ltd.
Registration Date : 2022-01-24
Registration Number : 20220124-209-J-1222
Manufacturer Name : PharmaZell GmbH
Manufacturer Address : Rosenheimer Straße 43 83064 Raubling Germany
Available Reg Filing : EU, CA, BR, TH, ID |
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-23
Pay. Date : 2014-05-14
DMF Number : 11568
Submission : 1995-06-29
Status : Active
Type : II
Certificate Number : R1-CEP 2012-297 - Rev 00
Issue Date : 2019-05-02
Type : Chemical
Substance Number : 2103
Status : Valid
NDC Package Code : 12780-4900
Start Marketing Date : 1995-06-29
End Marketing Date : 2028-04-22
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-03-04
Pay. Date : 2013-08-28
DMF Number : 23537
Submission : 2010-02-04
Status : Active
Type : II
Certificate Number : R1-CEP 2010-183 - Rev 01
Issue Date : 2019-04-09
Type : Chemical
Substance Number : 2103
Status : Valid
Registration Number : 224MF10096
Registrant's Address : No. 61, Ln. 309, Haihu N. Rd. , Luzhu Dist. , Taoyuan City 33856, Taiwan
Initial Date of Registration : 2012-05-08
Latest Date of Registration : --
NDC Package Code : 68108-0340
Start Marketing Date : 2012-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2021-03-16
Registration Number : 20210316-209-J-662
Manufacturer Name : SCI Pharmtech, Inc
Manufacturer Address : No.61, Ln.309, Haihu N. Rd., Luzhu Dist. Taoyuan City 33856, Taiwan
Available Reg Filing : CA, CN |
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-24
Pay. Date : 2013-06-18
DMF Number : 11426
Submission : 1995-04-03
Status : Active
Type : II
Registration Number : 217MF11295
Registrant's Address : Via Matteotti 249,28062 CAMERI(NOVARA)/ITALY
Initial Date of Registration : 2005-12-22
Latest Date of Registration : --
NDC Package Code : 46016-0320
Start Marketing Date : 2006-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25588
Submission : 2012-03-20
Status : Active
Type : II
Date of Issue : 2019-10-07
Valid Till : 2022-07-02
Written Confirmation Number : WC-0226
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37964
Submission : 2023-02-09
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-01-04
Pay. Date : 2017-01-20
DMF Number : 13010
Submission : 1998-06-01
Status : Active
Type : II
NDC Package Code : 49706-0201
Start Marketing Date : 2010-01-08
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 8311
Submission : 1989-11-27
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20418
Submission : 2007-03-15
Status : Inactive
Type : II
Date of Issue : 2022-06-22
Valid Till : 2025-07-28
Written Confirmation Number : WC-0117
Address of the Firm :
NDC Package Code : 65015-671
Start Marketing Date : 2015-02-17
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12691
Submission : 1997-10-09
Status : Inactive
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Propafenone Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Propafenone Hydrochloride, including repackagers and relabelers. The FDA regulates Propafenone Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Propafenone Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Propafenone Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Propafenone Hydrochloride supplier is an individual or a company that provides Propafenone Hydrochloride active pharmaceutical ingredient (API) or Propafenone Hydrochloride finished formulations upon request. The Propafenone Hydrochloride suppliers may include Propafenone Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Propafenone Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Propafenone Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Propafenone Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Propafenone Hydrochloride DMFs exist exist since differing nations have different regulations, such as Propafenone Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Propafenone Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Propafenone Hydrochloride USDMF includes data on Propafenone Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Propafenone Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Propafenone Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Propafenone Hydrochloride Drug Master File in Japan (Propafenone Hydrochloride JDMF) empowers Propafenone Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Propafenone Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Propafenone Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Propafenone Hydrochloride suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Propafenone Hydrochloride Drug Master File in Korea (Propafenone Hydrochloride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Propafenone Hydrochloride. The MFDS reviews the Propafenone Hydrochloride KDMF as part of the drug registration process and uses the information provided in the Propafenone Hydrochloride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Propafenone Hydrochloride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Propafenone Hydrochloride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Propafenone Hydrochloride suppliers with KDMF on PharmaCompass.
A Propafenone Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Propafenone Hydrochloride Certificate of Suitability (COS). The purpose of a Propafenone Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Propafenone Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Propafenone Hydrochloride to their clients by showing that a Propafenone Hydrochloride CEP has been issued for it. The manufacturer submits a Propafenone Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Propafenone Hydrochloride CEP holder for the record. Additionally, the data presented in the Propafenone Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Propafenone Hydrochloride DMF.
A Propafenone Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Propafenone Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Propafenone Hydrochloride suppliers with CEP (COS) on PharmaCompass.
A Propafenone Hydrochloride written confirmation (Propafenone Hydrochloride WC) is an official document issued by a regulatory agency to a Propafenone Hydrochloride manufacturer, verifying that the manufacturing facility of a Propafenone Hydrochloride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Propafenone Hydrochloride APIs or Propafenone Hydrochloride finished pharmaceutical products to another nation, regulatory agencies frequently require a Propafenone Hydrochloride WC (written confirmation) as part of the regulatory process.
click here to find a list of Propafenone Hydrochloride suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Propafenone Hydrochloride as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Propafenone Hydrochloride API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Propafenone Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Propafenone Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Propafenone Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Propafenone Hydrochloride suppliers with NDC on PharmaCompass.
Propafenone Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Propafenone Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Propafenone Hydrochloride GMP manufacturer or Propafenone Hydrochloride GMP API supplier for your needs.
A Propafenone Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Propafenone Hydrochloride's compliance with Propafenone Hydrochloride specifications and serves as a tool for batch-level quality control.
Propafenone Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Propafenone Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Propafenone Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Propafenone Hydrochloride EP), Propafenone Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Propafenone Hydrochloride USP).
LOOKING FOR A SUPPLIER?